Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana

The ongoing SARS-CoV-2 coronavirus pandemic of 2020–2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on Nicotiana benthamiana produced mAb therapeutics with high batch-to-batch reproducibility and f...

Descripción completa

Detalles Bibliográficos
Autores principales: Swope, Kelsi, Morton, Josh, Pogue, Gregory P., Burden, Leigh, Partain, Nicholas, Hume, Steve, Shepherd, John, Simpson, Carrie A., Brennan, Miles B., Furman, Thomas C., Kingrey-Gebe, Sheila, Martinez, Theresa, McDonough, Jim, Pauly, Michael H., Whaley, Kevin J., Zeitlin, Larry, Bratcher, Barry, Haydon, Hugh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744878/
https://www.ncbi.nlm.nih.gov/pubmed/35000569
http://dx.doi.org/10.1080/19420862.2021.2013594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744878/
https://www.ncbi.nlm.nih.gov/pubmed/35000569
http://dx.doi.org/10.1080/19420862.2021.2013594

Ejemplares similares